Latest "Therapure Biopharma" News Stories

08:51 EDT 20th July 2018 | BioPortfolio

Here are the most relevant search results for "Therapure Biopharma" found in our extensive news archives from over 250 global news sources.

More Information about Therapure Biopharma on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Therapure Biopharma for you to read. Along with our medical data and news we also list Therapure Biopharma Clinical Trials, which are updated daily. BioPortfolio also has a large database of Therapure Biopharma Companies for you to search.

Showing "Therapure Biopharma" News Articles 1–25 of 2,200+

Extremely Relevant

Therapure Biopharma spins out Evolve Biologics


Therapure Biopharma Launches Biologics Division

New plasma products and technology company-Evolve Biologics-led by Blaine Forshage as CEO

Evolve Biologics, Therapure Biopharma’s Biologics Division, Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering

Evolve Biologics, the biologics division of Therapure Biopharma Inc., today announced that in February 2018 the company confidentially submitted a draft registration statement on Form F-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to the proposed initial public offering of its common shares. The initial public offering is exp...

Therapure Biopharma Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 15032018] Prices from USD $250

SummaryTherapure Biopharma Inc Therapure is a biopharmaceutical company that offers research and development services. The company's activities include manufacture, development, purification, and packaging of therapeutic proteins and followon biologics. It operates through its division therapure biomanufacturing, therapure innovations and therapure biologics. Therapure's therapure biomanufacturing...

PDL BioPharma: Buy or Sell

It’s not unusual for a biopharma company, given enough time, to have its ups and downs. But PDL BioPharma’s roller-coaster ride has been more dramatic than most.

KBI Biopharma: How to stand out in the CMO space

KBI Biopharma is a CMO focused exclusively on biologics. Bernardo Estupinan-Gaisbauer, Vice President – Business Development at KBI Biopharma, discusses their strategy for partnering, and the challenges of staying competitive in the CMO sector.

BioPharma Ambition 2018: Live updates from an all-island event

In between NIBRT site tours and tax workshops in Dublin Castle, Biopharma-Reporter is covering BioPharma Ambition on the Emerald Isle.

#jobs #lifescience Biopharma/Biotech

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Biopharma/Biotech .CA-South San Francisco, Biopharma/Biotech Company: Amgen, Inc. Location: South San Francisco, CA Position Type: Full Time Experience: Unspecified Education: Unspecified Amgen, Inc. has opptys in South San … Continue reading → Cet article #jobs #l...

Therapure Biopharma Launches Biologics Division as Evolve Biologics™, an Innovative Plasma-Derived Therapeutics Company

New plasma products and technology company led by experienced senior management team, with industry veteran Blaine Forshage as Chief Executive Officer Dedicated to commercializing proprietary PlasmaCap EBA® technology to efficiently meet growing global demand for plasma-derived therapeutics Pipeline of product candidates, initially focus...

Prestige Biopharma And Alvogen Announce License And Supply Agreement To Commercialize Biosimilar

NewsPrestige BioPharma and Alvogen have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma´s Trastuzumab biosimilar in Central and Eastern Europe.

#jobs #lifescience Director of Corporate Communications – Ph III Biopharma

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Director of Corporate Communications – Ph III Biopharma .MA-Lexington, If you are a Director of Corporate Communications with rare disease, ophthalmology, and/or nephrology experience, please read on! What … Continue reading → Cet article #jobs #lifescience D...

Tasly Biopharma Pays $48 Million to Buy Out JV Partner, Transgene

Tasly Biopharma paid $48 million in stock to buy out its China JV partner Transgene (P: TNG), which holds China rights to two Transgene products: T601, an oncolytic virus, and T101, a therapeutic vaccine. The stock represents 2.53% of Tasly Biopharma's capital after a pre-IPO investment round, which priced at the same time as the Transgene transaction. Tasly Biopharma, the novel drug subsidiary of...

Evolve Biologics™ Reaches Major Milestones in Phase III Trial for PlasmaCap™ IG (Intravenous Immunoglobulin), Including Dosing of First Pediatric Patient

Half of Required Infusions Now Successfully Administered in Adult Portion of Study A Prospective, Open-Label, Multicenter Study of the Efficacy, Safety, Tolerability and Pharmacokinetics of PlasmaCap IG in Adults and Children with Primary Immune Deficiency Diseases Evolve Biologics (“Evolve”), a division of Therapure Biopharma Inc. ...

#jobs #lifescience (Senior) Manager, Regulatory Operations – Biopharma

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: (Senior) Manager, Regulatory Operations – Biopharma .MA-Waltham, Direct-hire opportunity for a Manager or Associate Director of Regulatory Operations! This is a newly created role with a growing biotech … Continue reading → Cet article #jobs #lifescience (Sen...

Hemispherx Biopharma And UNMC Take On Pancreatic Cancer

NewsThe University of Nebraska Medical Center and Hemispherx Biopharma, Inc. are joining forces to take on pancreatic cancer, one of the most deadly forms of cancer.

New Jersey Innovation Institute to Prep Biopharma Workforce

Launches training program for biopharma professionals

Rentschler Biopharma Appoints New VP

Dr. Thomas Rösch boasts over 16 years of industry experience, and will head the Biopharma Engineering & Technology unit

New Disposable Control Valve Is Designed for BioPharma

This specialty instrument was developed in response to the biopharma industry’s rapidly expanding requirements

PDL BioPharma drops pursuit of Neos

PDL BioPharma today officially announced it will no longer pursue its proposed acquisition of US modified-release…

Top 5 Women Executives in the Biopharma Industry by Compensation

Not only are women generally underrepresented in the biopharma industry, but compared to many of the top male executives, underpaid. Here’s a closer look at the top five female executives by pay in the biopharma industry.

Enteris BioPharma's Partner Doses First Patient With New Drug

NewsCara Therapeutics, partnering with Enteris BioPharma, has initiated the Phase One clinical trial of its oral Korsuva in patients with chronic liver disease. Enteris will continue to manufacture the oral tablet formulation through Phase Two.

Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease

DUBLIN and HERTFORDSHIRE, England and PITTSBURGH, Jan. 29, 2018 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced that the U.S. Food and Drug...

Tasly Biopharma Raises $84.5 Million in Pre-IPO Round

Tasly Biopharma of Shanghai raised $84.5 million in new capital from a group of investors that included Ally Bridge. The funding is a pre-IPO round as Tasly is planning to list on the Hong Kong Exchange. The investors received a 4.5% stake in Tasly Biopharma, implying a $1.9 billion pre-IPO valuation. Tasly Biopharma is a subsidiary of Tasly Pharma. As a separate part of the transaction, Transgene...

Sutro Biopharma: origins, platform technology and competitive advantage

In this interview, filmed at BioPharm in San Francisco, Dr Fintan Walton speaks with William J Newell, Chief Executive Officer at Sutro Biopharma, a biopharma drug development firm They discuss the company's: • origins and business model • collaborations • platform technology, how it works and its advantages over its competitors’ platforms • plans for the future

Landos Biopharma kicks off Phase 1 clinical study for its treatment of IBD

Landos Biopharma CEO Josep-Bassaganya-Riera tells Proactive Investors the biopharma has very high expectations on how the company's drug, BT-11, will move forward. Landos began dosing the drug in Phase 1 clinical study in July, they anticipate results in November.

Quick Search


News Quicklinks